🎉 M&A multiples are live!
Check it out!

Eris Lifesciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Eris Lifesciences and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Eris Lifesciences Overview

About Eris Lifesciences

Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.


Founded

2007

HQ

India
Employees

3.1K+

Website

eris.co.in

Financials

LTM Revenue $346M

LTM EBITDA $121M

EV

$2.5B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Eris Lifesciences Financials

Eris Lifesciences has a last 12-month revenue of $346M and a last 12-month EBITDA of $121M.

In the most recent fiscal year, Eris Lifesciences achieved revenue of $231M and an EBITDA of $81.1M.

Eris Lifesciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Eris Lifesciences valuation multiples based on analyst estimates

Eris Lifesciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $193M $231M XXX XXX XXX
Gross Profit $124M $152M XXX XXX XXX
Gross Margin 64% 66% XXX XXX XXX
EBITDA $63.6M $81.1M XXX XXX XXX
EBITDA Margin 33% 35% XXX XXX XXX
Net Profit $47.2M $44.4M XXX XXX XXX
Net Margin 24% 19% XXX XXX XXX
Net Debt n/a $89.9M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Eris Lifesciences Stock Performance

As of April 15, 2025, Eris Lifesciences's stock price is INR 1384 (or $16).

Eris Lifesciences has current market cap of INR 189B (or $2.2B), and EV of INR 213B (or $2.5B).

See Eris Lifesciences trading valuation data

Eris Lifesciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.5B $2.2B XXX XXX XXX XXX $0.35

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Eris Lifesciences Valuation Multiples

As of April 15, 2025, Eris Lifesciences has market cap of $2.2B and EV of $2.5B.

Eris Lifesciences's trades at 7.2x LTM EV/Revenue multiple, and 20.5x LTM EBITDA.

Analysts estimate Eris Lifesciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Eris Lifesciences and 10K+ public comps

Eris Lifesciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.5B XXX XXX XXX
EV/Revenue 7.8x XXX XXX XXX
EV/EBITDA 22.4x XXX XXX XXX
P/E 49.2x XXX XXX XXX
P/E/Growth 1.4x XXX XXX XXX
EV/FCF -74.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Eris Lifesciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Eris Lifesciences Valuation Multiples

Eris Lifesciences's NTM/LTM revenue growth is 14%

Eris Lifesciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $42K for the same period.

Over next 12 months, Eris Lifesciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Eris Lifesciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Eris Lifesciences and other 10K+ public comps

Eris Lifesciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 20% XXX XXX XXX XXX
EBITDA Margin 35% XXX XXX XXX XXX
EBITDA Growth 28% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 49% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $42K XXX XXX XXX XXX
S&M Expenses to Revenue 9% XXX XXX XXX XXX
G&A Expenses to Revenue 4% XXX XXX XXX XXX
R&D Expenses to Revenue 0% XXX XXX XXX XXX
Opex to Revenue 56% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Eris Lifesciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Eris Lifesciences M&A and Investment Activity

Eris Lifesciences acquired  XXX companies to date.

Last acquisition by Eris Lifesciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Eris Lifesciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Eris Lifesciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Eris Lifesciences

When was Eris Lifesciences founded? Eris Lifesciences was founded in 2007.
Where is Eris Lifesciences headquartered? Eris Lifesciences is headquartered in India.
How many employees does Eris Lifesciences have? As of today, Eris Lifesciences has 3.1K+ employees.
Is Eris Lifesciences publicy listed? Yes, Eris Lifesciences is a public company listed on BOM.
What is the stock symbol of Eris Lifesciences? Eris Lifesciences trades under 540596 ticker.
When did Eris Lifesciences go public? Eris Lifesciences went public in 2017.
Who are competitors of Eris Lifesciences? Similar companies to Eris Lifesciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Eris Lifesciences? Eris Lifesciences's current market cap is $2.2B
What is the current revenue of Eris Lifesciences? Eris Lifesciences's last 12-month revenue is $346M.
What is the current EBITDA of Eris Lifesciences? Eris Lifesciences's last 12-month EBITDA is $121M.
What is the current EV/Revenue multiple of Eris Lifesciences? Current revenue multiple of Eris Lifesciences is 7.2x.
What is the current EV/EBITDA multiple of Eris Lifesciences? Current EBITDA multiple of Eris Lifesciences is 20.5x.
What is the current revenue growth of Eris Lifesciences? Eris Lifesciences revenue growth between 2023 and 2024 was 20%.
Is Eris Lifesciences profitable? Yes, Eris Lifesciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.